Literature DB >> 10391282

Gene transfection of hepatocyte growth factor attenuates reperfusion injury in the heart.

H Ueda1, Y Sawa, K Matsumoto, S Kitagawa-Sakakida, Y Kawahira, T Nakamura, Y Kaneda, H Matsuda.   

Abstract

BACKGROUND: Hepatocyte growth factor (HGF), a ligand for the c-Met receptor tyrosine kinase, plays a role as organotrophic factor for regeneration of various organs. HGF has an angiogenic activity and exhibits a potent antiapoptotic activity in several types of cells. Although HGF and the c-Met/HGF receptor are expressed in the heart, the role of HGF in the heart has remained unknown.
METHODS: After we analyzed changes in expression of endogenous HGF and c-Met mRNA levels in the rat left ventricle after myocardial infarction, the human HGF gene in hemagglutinating virus of Japan (HVJ)-liposome was transfected into the normal whole rat heart. Three days after transfection, the heart was subjected to global warm ischemia and subsequent reperfusion, followed by assessment of its cardiac functions.
RESULTS: Both HGF and c-Met/HGF receptor mRNAs were expressed in adult rat heart, and c-Met/HGF receptor mRNA was upregulated in response to myocardial infarction. HGF-transfected heart showed significant increase of human HGF protein level in the heart. Cardiac functions in terms of the left ventricular developed pressure, maximum dp/dt, and pressure rate product in hearts with HGF gene transfection were significantly superior to those in control hearts. In addition, leakage of creatine phosphokinase in the coronary artery effluent in hearts with HGF gene transfection was significantly lower than that in control hearts.
CONCLUSIONS: These data indicated that both HGF and c-Met/HGF receptor mRNAs were upregulated in response to myocardial ischemic injury, and that HGF is likely to have a cytoprotective effect on cardiac tissue, presumably through the c-Met/HGF receptor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10391282     DOI: 10.1016/s0003-4975(99)00279-9

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  10 in total

1.  An ovine preimmune foetal model to study the effect of cellular therapies for myocardic diseases.

Authors:  L Petrizzi; A Ioannoni; V Varasano; V Russo; A Mauro; A Mazzola
Journal:  Vet Res Commun       Date:  2008-09       Impact factor: 2.459

2.  Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo.

Authors:  X Xin; S Yang; G Ingle; C Zlot; L Rangell; J Kowalski; R Schwall; N Ferrara; M E Gerritsen
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

3.  A mouse model for spatial and temporal expression of HGF in the heart.

Authors:  Ilan Riess; Valentina Sala; Christian Leo; Marco Demaria; Stefano Gatti; Simona Gallo; Amandine Fitou; Ombretta Boero; Renzo Levi; Ivan Cuccovillo; Fabiola Molla; Noeleen De Angelis; Lidia Staszewsky; Roberto Latini; Tiziana Crepaldi
Journal:  Transgenic Res       Date:  2011-03-01       Impact factor: 2.788

4.  Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF.

Authors:  T Nakamura; S Mizuno; K Matsumoto; Y Sawa; H Matsuda; T Nakamura
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

5.  Sustained expression of naked plasmid DNA encoding hepatocyte growth factor in mice promotes liver and overall body growth.

Authors:  J Yang; S Chen; L Huang; G K Michalopoulos; Y Liu
Journal:  Hepatology       Date:  2001-04       Impact factor: 17.425

Review 6.  Myoblast-based cell transplantation.

Authors:  Philippe Menasché
Journal:  Heart Fail Rev       Date:  2003-07       Impact factor: 4.214

7.  Activation of Notch-mediated protective signaling in the myocardium.

Authors:  Natalie A Gude; Gregory Emmanuel; Weitao Wu; Christopher T Cottage; Kimberlee Fischer; Pearl Quijada; John A Muraski; Roberto Alvarez; Marta Rubio; Eric Schaefer; Mark A Sussman
Journal:  Circ Res       Date:  2008-03-27       Impact factor: 17.367

8.  Cationic liposomes loaded with proapoptotic peptide D-(KLAKLAK)(2) and Bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy.

Authors:  Young Tag Ko; Claudio Falcao; Vladimir P Torchilin
Journal:  Mol Pharm       Date:  2009 May-Jun       Impact factor: 4.939

9.  Safety and pharmacokinetics of recombinant human hepatocyte growth factor (rh-HGF) in patients with fulminant hepatitis: a phase I/II clinical trial, following preclinical studies to ensure safety.

Authors:  Akio Ido; Akihiro Moriuchi; Masatsugu Numata; Toshinori Murayama; Satoshi Teramukai; Hiroyuki Marusawa; Naohisa Yamaji; Hitoshi Setoyama; Il-Deok Kim; Tsutomu Chiba; Shuji Higuchi; Masayuki Yokode; Masanori Fukushima; Akira Shimizu; Hirohito Tsubouchi
Journal:  J Transl Med       Date:  2011-05-08       Impact factor: 5.531

10.  Met and Cxcr4 cooperate to protect skeletal muscle stem cells against inflammation-induced damage during regeneration.

Authors:  Ines Lahmann; Joscha Griger; Jie-Shin Chen; Yao Zhang; Markus Schuelke; Carmen Birchmeier
Journal:  Elife       Date:  2021-08-05       Impact factor: 8.140

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.